drugset / Trial / NCT00347061
Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary: To assess the safety of SL77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to BPH. Secondary: * To provide the information on the efficacy of SL77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to BPH. * To document the plasma concentration of SL77.0499-10 after repeated administration of SL77.0499-10 10mg administered once daily in patients with lower urinary tract symptoms related to BPH.
Timeline
- Start
- 2006-05
- Primary completion
- 2007-10
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alfuzosin | Small molecule | 10 mg | — |